[{"id":"fb5a3d64-2b8f-44c4-84f0-e927e52ab2a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04939051","created_at":"2024-02-29T18:31:43.001Z","updated_at":"2025-02-25T13:35:51.854Z","phase":"Phase 2","brief_title":"Obeticholic Acid for Prevention in Barrett's Esophagus","source_id_and_acronym":"NCT04939051","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FGF19 • SOX2 • CASP3 • FGF • CDX2","pipe":"","alterations":" ","tags":["FGF19 • SOX2 • CASP3 • FGF • CDX2"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/03/2024","start_date":" 01/03/2024","primary_txt":" Primary completion: 09/29/2025","primary_completion_date":" 09/29/2025","study_txt":" Completion: 09/29/2026","study_completion_date":" 09/29/2026","last_update_posted":"2025-02-21"},{"id":"be9b6599-a34b-403f-ab30-2d9525c708df","acronym":"FORMOSA","url":"https://clinicaltrials.gov/study/NCT05572944","created_at":"2022-10-10T14:05:27.382Z","updated_at":"2024-07-02T16:35:19.849Z","phase":"","brief_title":"Formatting the Risk Prediction Models for Never-Smoking Lung Cancer","source_id_and_acronym":"NCT05572944 - FORMOSA","lead_sponsor":"Chung Shan Medical University","biomarkers":" CTAG1B • SOX2","pipe":"","alterations":" ","tags":["CTAG1B • SOX2"],"overall_status":"Recruiting","enrollment":" Enrollment 10000","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-02-12"},{"id":"f6f05048-0e6c-4802-9b3f-3f1e875e0073","acronym":"","url":"https://clinicaltrials.gov/study/NCT05429710","created_at":"2022-06-23T16:00:10.054Z","updated_at":"2024-07-02T16:36:08.410Z","phase":"","brief_title":"SOX2 \u0026 PDL1 Expression on Urinary Bladder Carcinoma","source_id_and_acronym":"NCT05429710","lead_sponsor":"Sohag University","biomarkers":" PD-L1 • SOX2","pipe":" | ","alterations":" SOX2 expression","tags":["PD-L1 • SOX2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SOX2 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-06-23"},{"id":"00fc36b5-fb5c-4743-870c-ddf1ebb39ac5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04854044","created_at":"2021-04-22T21:53:11.171Z","updated_at":"2024-07-02T16:36:30.399Z","phase":"Phase 1b","brief_title":"ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma","source_id_and_acronym":"NCT04854044","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" SOX2 • NANOG","pipe":"","alterations":" ","tags":["SOX2 • NANOG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2021-05-12"},{"id":"69112ba3-2ae8-4897-864e-b49a99d79bf1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03771404","created_at":"2021-01-18T18:39:31.761Z","updated_at":"2024-07-02T16:37:04.768Z","phase":"","brief_title":"NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized \"Liquid Biopsy\"","source_id_and_acronym":"NCT03771404","lead_sponsor":"Hellenic Oncology Research Group","biomarkers":" EGFR • HER-2 • KRAS • BRAF • TP53 • PIK3CA • NRAS • PTEN • FGFR1 • MAP2K1 • AKT1 • SOX2 • DDR2 • TP63","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation • PTEN mutation • MAP2K1 mutation • AKT1 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • TP53 • PIK3CA • NRAS • PTEN • FGFR1 • MAP2K1 • AKT1 • SOX2 • DDR2 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation • PTEN mutation • MAP2K1 mutation • AKT1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 01/05/2018","start_date":" 01/05/2018","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2018-12-11"},{"id":"e722bb9a-1b52-491f-aa47-aef3ea3920fe","acronym":"STEMRI","url":"https://clinicaltrials.gov/study/NCT01872221","created_at":"2021-01-18T08:23:11.135Z","updated_at":"2024-07-02T16:37:07.485Z","phase":"","brief_title":"Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study","source_id_and_acronym":"NCT01872221 - STEMRI","lead_sponsor":"Institut Claudius Regaud","biomarkers":" SOX2 • OLIG2","pipe":" | ","alterations":" CD133 expression","tags":["SOX2 • OLIG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD133 expression"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 04/01/2018","study_completion_date":" 04/01/2018","last_update_posted":"2018-08-27"}]